Skip to content

STI Knowledge and HPV Vaccine Acceptance in Bamako, Mali in 2012

Knowledge, Attitudes, Practices and Willingness to Vaccinate in Preparation for the Introduction of HPV Vaccines in Bamako, Mali

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05767138
Enrollment
301
Registered
2023-03-14
Start date
2011-03-31
Completion date
2011-06-30
Last updated
2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV, HPV-Related Cervical Carcinoma

Keywords

Mali, Bamako, Survey

Brief summary

Although screening for pre-cancerous cervical lesions and human papilloma virus (HPV) vaccination are accepted and effective means to prevent cervical cancer, women in Mali have limited access to these interventions. In addition, cervical cancer prevention by HPV vaccination has been controversial in some settings. To reduce cervical cancer prevalence and increase HPV vaccine uptake, it is important to understand the level of knowledge about cervical cancer screening and practices related to vaccination in at-risk populations. In this study, the level of knowledge about HPV and cervical cancer and attitudes towards vaccination were assessed among 301 participants (male and female, adults and adolescents) in a house-to-house survey in two urban neighborhoods in Bamako, Mali. The survey was combined with a brief educational session on HPV. Prior to the education session, overall knowledge of HPV infection and cervical cancer was very low: only 8% knew that HPV is a sexually transmitted infection (STI). Less than 20% of women had ever consulted a gynecologist and less than 3% had ever had cervical cancer screening. After hearing a description of HPV vaccine, more than 80% would accept HPV vaccination; fathers and husbands were identified as primary decisions makers and local clinics or the home as preferred sites for vaccination. This study provides information on STI knowledge and vaccine acceptance in Bamako, Mali in 2012, prior to the introduction of HPV vaccination.

Interventions

BEHAVIORALHPV Vaccine Acceptance Survey

Sponsors

Merck Sharp & Dohme LLC
CollaboratorINDUSTRY
Global Alliance to Immunize Against AIDS Vaccine Foundation
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 12-17 years of age, with guardian consent * 18 years or older * Male or Female * Living in Mèkin-Sikoro and Djikoroni

Exclusion criteria

* 12-17 years of age, without guardian consent * \<12 years of age * Living outside Mèkin-Sikoro and Djikoroni

Design outcomes

Primary

MeasureTime frameDescription
Participants' acceptance of the vaccineimmediately after the interventionNumber of participants willing to be vaccinated against HPV and their vaccination preferences after educational sessions

Secondary

MeasureTime frameDescription
Knowledge of STIs, HPV, and Cervical Cancerimmediately after the interventionKnowledge Question asked before and after educational session

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026